Discover 645 paid clinical trials in Nebraska. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Nebraska provides a variety of paid research opportunities for both healthy volunteers and individuals with specific medical concerns. Research institutions in Omaha, Lincoln, and Bellevue are recruiting participants, offering access to advanced treatments and dedicated medical care.
Filter
1
Filter results
Results: 645
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
for
Metastatic Gastric Adenocarcinoma,
Location: Westbrook ME, Florham Park NJ, Flemington NJ,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT07043400
Phase 3, Recruiting
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
for
Pneumococcal Disease
Location: Fall River MA, East Syracuse NY, Richmond VA,
Sponsor: Pfizer
Sex: All
Age: 1 - 17
Code: NCT07660198
Phase 3, Recruiting
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
for
Non-Arteritic Anterior Ischemic Optic Neuropathy
Location: Boston MA, Philadelphia PA, Baltimore MD, Durham NC,
Sponsor: Dompé Farmaceutici S.p.A
Sex: All
Age: 50 - 70+
Code: NCT07453888
Phase 3, Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
for
Asthma
Location: Hawthorne NY, The Bronx NY, Ocean City NJ, New York NY,
Sponsor: AstraZeneca
Sex: All
Age: 12 - 17
Code: NCT06307665
Phase 3, Recruiting
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Location: Bath ME, Portland ME, Scarborough ME, South Portland ME,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT06958328
Phase 3, Recruiting
NORM-HF Pivotal Study
for
Heart Failure, NYHA Class III Heart Failure,
Location: Boston MA, Philadelphia PA, Chapel Hill NC, Columbia SC,
Sponsor: Foundry Innovation & Research 1, Limited (FIRE1)
Sex: All
Age: 18+
Code: NCT07574593
Recruiting
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
for
Focal Seizure, Epilepsy, Focal Epilepsy
Location: New York NY, Raleigh NC, Miami FL, Maitland FL,
Sponsor: Rapport Therapeutics Inc.
Sex: All
Age: 18 - 70+
Code: NCT07594119
Phase 3, Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
for
Core Binding Factor Acute Myeloid Leukemia
Location: Boston MA, Providence RI, The Bronx NY, Wilkes-Barre PA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 59
Code: NCT06917911
Phase 2, Recruiting
Improving Exercise Adherence With App Technology for At-Risk Adults Living in Rural Kansas and Nebraska
for
Sedentary Middle Age and Older Aged Adults
Location: Omaha NE, Emporia KS
Sponsor: Creighton University
Sex: All
Age: 40 - 70+
Code: NCT07171255
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
for
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Location: Rimouski, Boston MA, Worcester MA, Hartford CT, Quebec,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06793215
Phase 3, Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
for
Metastatic Non-small Cell Lung Cancer With MTAP Deletion